CureVac (NASDAQ:CVAC) Shares Gap Up to $3.34

Shares of CureVac (NASDAQ:CVACGet Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $3.34, but opened at $3.79. CureVac shares last traded at $3.60, with a volume of 2,671,910 shares trading hands.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CVAC. SVB Leerink cut CureVac from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $12.00 to $4.00 in a research note on Thursday, April 25th. Guggenheim reaffirmed a “neutral” rating on shares of CureVac in a research note on Friday, April 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price target on shares of CureVac in a research note on Wednesday. Finally, Leerink Partnrs cut CureVac from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

Check Out Our Latest Report on CVAC

CureVac Price Performance

The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.09 and a current ratio of 2.25. The company has a 50-day moving average of $3.47 and a 200-day moving average of $3.45. The firm has a market capitalization of $698.51 million, a price-to-earnings ratio of -2.35 and a beta of 2.64.

CureVac (NASDAQ:CVACGet Free Report) last issued its quarterly earnings data on Thursday, May 23rd. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.12). CureVac had a negative net margin of 463.49% and a negative return on equity of 49.22%. The business had revenue of $13.43 million during the quarter, compared to analyst estimates of $14.51 million. As a group, research analysts anticipate that CureVac will post -1.11 EPS for the current fiscal year.

Hedge Funds Weigh In On CureVac

Large investors have recently bought and sold shares of the company. Vontobel Holding Ltd. acquired a new position in CureVac during the 4th quarter worth approximately $45,000. Ballentine Partners LLC acquired a new position in CureVac during the 1st quarter worth approximately $38,000. Vanguard Personalized Indexing Management LLC acquired a new position in CureVac during the 4th quarter worth approximately $68,000. International Assets Investment Management LLC acquired a new position in CureVac during the 4th quarter worth approximately $71,000. Finally, Aristides Capital LLC acquired a new position in CureVac during the 4th quarter worth approximately $100,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

CureVac Company Profile

(Get Free Report)

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

Featured Articles

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.